RANCHO CORDOVA, Calif. and LOS ANGELES, Oct. 10, 2013 (GLOBE NEWSWIRE) -- TotipotentRX Corporation and ThermoGenesis Corp. (Nasdaq:KOOL) today announced two upcoming presentations at a pre-conference symposium of the American Association of Blood Banks Annual Meeting in Denver, CO on Sunday, October 13 th at 1:30 pm (MDT). The first presentation will be initial results data from TotipotentRX's 24 month case study (Pilot Safety Trial) using its stem cell combination product AMIRST therapy in patients with acute myocardial infarction. The second presentation will be given on the post-transplant survival and engraftment rates of pediatric patients receiving mismatched (allogeneic) bone marrow transplants processed with the ThermoGenesis MXP ® MarrowXpress ® stem cell processing technology. The presentations will be given by Kenneth Harris, Study Director and CEO of TotipotentRX.
- The BioArchive ® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- AXP ® AutoXpress ® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP ® MarrowXpress ® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
- The Res-Q TM 60 (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).